{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:24:39Z","timestamp":1790447079565,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Canada has seen a rise in substance-related accidental acute toxicity deaths (AATDs) in recent years. Research indicates that fentanyl opioids, non-fentanyl opioids, and stimulants are classes of concern and that multidrug AATDs have increased. However, there is limited information regarding the specific substances involved. This study aims to identify the substances and substance combinations as well as substance classes and substance class combinations most often involved in AATDs across Canada between 2016 and 2017. It also examines variations in substances by year and across sociodemographic, socioeconomic, and geographic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were abstracted from the coroner and medical examiner files of all AATDs that occurred across Canada between 2016 and 2017. Top substances and classes detected in or contributing to AATDs were identified based on toxicology reports and cause of death statements. AATDs were stratified by year of death, age, sex, residence community type, neighbourhood income quintile, and province\/region to understand variations in the substances contributing to AATDs. Combinations of substances and classes contributing to death were examined with UpSet plots and trends of select substances were visualized over time with ribbon charts. An algorithm was developed to report the source and origin of the substances based on prescription history and scene evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fentanyl, cocaine, alcohol, and methamphetamine were the top substances contributing to the 7,902 AATDs identified between 2016 and 2017 in Canada. While stimulants and opioids were the most common substance classes contributing to AATDs, other classes, including benzodiazepines and acetaminophen also emerged as classes among the top contributors. Between 2016 and 2017, the proportion of AATDs attributable to diacetylmorphine (heroin) per quarter decreased while the proportion of AATDs attributable to carfentanil per quarter increased. AATDs involving more than one substance occurred across all sociodemographic, socioeconomic, and geographic groups. Substances contributing to AATDs more commonly originated from non-pharmaceutical sources than from pharmaceutical sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and impacts<\/jats:title>\n                    <jats:p>Specific substances and substance combinations contributing to deaths vary over time and geographic areas. Opioids and stimulants are both detected in and contribute to a majority of AATDs, but the substance-related acute toxicity death crisis is complex and attributable to many substance classes. Understanding these differences will allow for targeted substance-related policies, prevention, and harm reduction efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-22777-2","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:16:49Z","timestamp":1764749809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Substances and substance combinations among accidental substance-related acute toxicity deaths (AATDs) in Canada from 2016 to 2017"],"prefix":"10.1186","volume":"26","author":[{"given":"Raahyma","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Rotondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keltie","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Leung Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"VanSteelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"17\u201318","key":"22777_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1503\/cmaj.160290","volume":"188","author":"B Fischer","year":"2016","unstructured":"Fischer B, Rehm J, Tyndall M. Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. Can Med Assoc J. 2016;188(17\u201318):1240\u20133. https:\/\/doi.org\/10.1503\/cmaj.160290.","journal-title":"Can Med Assoc J"},{"key":"22777_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103163","author":"B Fischer","year":"2021","unstructured":"Fischer B, O\u2019Keefe-Markman C, Lee A, Daldegan-Bueno D. \u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. Int J Drug Policy. 2021. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103163.","journal-title":"Int J Drug Policy"},{"key":"22777_CR3","unstructured":"Government of Canada. Government of Canada Actions on Opioids 2016 and 2017. 2017. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/actions-opioids-2016-2017.html."},{"key":"22777_CR4","unstructured":"Statistics Canada. Changes in life expectancy by selected causes of death, 2017. The Daily. 2017. Available from: https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/190530\/dq190530d-eng.htm."},{"key":"22777_CR5","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada. June 2023."},{"issue":"6","key":"22777_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","volume":"38","author":"L Baldwin","year":"2018","unstructured":"Baldwin L, Hwang J. Evidence synthesis-The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prevent Canada J. 2018;38(6):224. https:\/\/doi.org\/10.24095\/hpcdp.38.6.02.","journal-title":"Health Promot Chronic Dis Prevent Canada J"},{"issue":"1","key":"22777_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-12399-x","volume":"22","author":"S Konefal","year":"2022","unstructured":"Konefal S, Sherk A, Maloney-Hall B, Young M, Kent P, Biggar E. Polysubstance use poisoning deaths in Canada: an analysis of trends from 2014 to 2017 using mortality data. BMC Public Health. 2022;22(1):1\u20132. https:\/\/doi.org\/10.1186\/s12889-021-12399-x.","journal-title":"BMC Public Health"},{"key":"22777_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11469-022-00786-5","volume":"10","author":"J Snowdon","year":"2022","unstructured":"Snowdon J, Choi N. Unanticipated changes in drug overdose death rates in canada during the opioid crisis. Int J Ment Heal Addict. 2022;10:1\u20139. https:\/\/doi.org\/10.1007\/s11469-022-00786-5.","journal-title":"Int J Ment Heal Addict"},{"issue":"1","key":"22777_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","volume":"26","author":"WM Compton","year":"2021","unstructured":"Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the United States opioid crisis. Mol Psychiatry. 2021;26(1):41\u201350. https:\/\/doi.org\/10.1038\/s41380-020-00949-3.","journal-title":"Mol Psychiatry"},{"key":"22777_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2019.03.027","volume":"200","author":"JA Barocas","year":"2019","unstructured":"Barocas JA, Wang J, Marshall BD, et al. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019;200:59\u201363. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.03.027.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"22777_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.24095\/hpcdp.42.2.03","volume":"42","author":"M Boileau-Falardeau","year":"2022","unstructured":"Boileau-Falardeau M, Contreras G, Garipy G, Laprise C. Patterns and motivations of polysubstance use: A rapid review of the qualitative evidence. Health Promot Chronic Dis Prevent Canada. 2022;42(2):47. https:\/\/doi.org\/10.24095\/hpcdp.42.2.03.","journal-title":"Health Promot Chronic Dis Prevent Canada"},{"key":"22777_CR12","doi-asserted-by":"publisher","unstructured":"Crummy EA, O\u2019Neal TJ, Baskin BM, Ferguson SM. One is not enough: understanding and modeling polysubstance use. Front Neurosci. 2020:569. https:\/\/doi.org\/10.3389\/fnins.2020.00569.","DOI":"10.3389\/fnins.2020.00569"},{"issue":"4","key":"22777_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/ADM.0000000000000455","volume":"13","author":"AH Rogers","year":"2019","unstructured":"Rogers AH, Bakhshaie J, Buckner JD, Orr MF, Paulus DJ, Ditre JW, Zvolensky MJ. Opioid and cannabis co-use among adults with chronic pain: relations to substance misuse, mental health, and pain experience. J Addict Med. 2019;13(4):287\u201394. https:\/\/doi.org\/10.1097\/ADM.0000000000000455.","journal-title":"J Addict Med"},{"key":"22777_CR14","unstructured":"Canadian Institute for Health Information. Opioid prescribing in Canada: How are practices changing? Ottawa, ON: CIHI; 2019."},{"key":"22777_CR15","doi-asserted-by":"publisher","first-page":"k3207","DOI":"10.1136\/bmj.k3207","volume":"29","author":"T Gomes","year":"2018","unstructured":"Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario. Canada BMJ. 2018;29:k3207. https:\/\/doi.org\/10.1136\/bmj.k3207.","journal-title":"Canada BMJ"},{"key":"22777_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugalcdep.2018.06.028","volume":"191","author":"T Gomes","year":"2018","unstructured":"Gomes T, et al. Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: a multi-jurisdictional cross-sectional study. Drug Alcohol Depend. 2018;191:86\u201390. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.028.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"22777_CR17","doi-asserted-by":"publisher","first-page":"100187","DOI":"10.1016\/j.dadr.2023.100187","volume":"1","author":"I Noriega","year":"2023","unstructured":"Noriega I, Bhullar MK, Gilson TP, Flannery DJ, Deo V, Fulton S. A case study for local data surveillance in opioid overdose fatalities in Cuyahoga County, OH 2016\u20132020. Drug Alcohol Dependence Rep. 2023;1(8):100187.","journal-title":"Drug Alcohol Dependence Rep"},{"issue":"206","key":"22777_CR18","doi-asserted-by":"publisher","first-page":"107658","DOI":"10.1016\/j.drugalcdep.2019.107658","volume":"1","author":"B Ray","year":"2020","unstructured":"Ray B, Lowder E, Bailey K, Huynh P, Benton R, Watson D. Racial differences in overdose events and polydrug detection in Indianapolis, Indiana. Drug Alcohol Depend. 2020;1(206):107658.","journal-title":"Drug Alcohol Depend"},{"key":"22777_CR19","doi-asserted-by":"publisher","unstructured":"Rotondo J, VanSteelandt A, Kouyoumdjian F, Bowes MJ, Kakkar T, Jones G, Abele B, Murray R, Schleihauf E, Halverson J, Leason J, Huyer D, Jackson B, Bozat-Emre S, Shah D, Rees EE. Substance-Related Acute Toxicity Deaths in Canada from 2016 to 2017: Protocol for a Retrospective Chart Review Study of Coroner and Medical Examiner Files. JMIR Public Health and Surveillance. 07\/05\/2024:49981 (forthcoming\/in press). https:\/\/doi.org\/10.2196\/49981.","DOI":"10.2196\/49981"},{"key":"22777_CR20","unstructured":"Statistics Canada. Canadian coroner and medical examiner database: Annual report. 2015. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-214-x\/2012001\/int-eng.htm."},{"key":"22777_CR21","doi-asserted-by":"publisher","unstructured":"Davis GG, National Association of Medical Examiners, American College of Medical Toxicology Expert Panel on Evaluating and Reporting Opioid Deaths. Complete republication: National Association of Medical Examiners position paper: Recommendations for the investigation, diagnosis, and certification of deaths related to opioid drugs. J Med Toxicol. 2014;10(1):100\u2013106. https:\/\/doi.org\/10.1007\/s13181-013-0323-x.","DOI":"10.1007\/s13181-013-0323-x"},{"key":"22777_CR22","unstructured":"Statistics Canada. Postal Code OM Conversion File Plus (PCCF+). Ottawa (ON): StatCan. 2021. Available from: https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/82F0086X. Cited 2022 Jul 18."},{"key":"22777_CR23","unstructured":"Statistics Canada. Postal Code OM Conversion File (PCCF), Reference Guide. Ottawa (ON): StatCan. 2021. Available from: https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/92-154-G. Cited 2022 Jul 18."},{"key":"22777_CR24","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses (SAC). Area-level characteristics of substance-related acute toxicity deaths: a descriptive analysis of a national chart review study of coroner and medical examiner data. Ottawa: Public Health Agency of Canada; 2022. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research\/area-level-characteristics-substance-related-acute-toxicity-deaths-analysis-coroner-medical-examiner-data.html."},{"key":"22777_CR25","unstructured":"R Core Team. Qicharts: Quality Improvement Charts. R package version 0.5.8. 2022. Available from: https:\/\/cran.r-project.org\/web\/packages\/qicharts\/qicharts.pdf."},{"key":"22777_CR26","unstructured":"HESA. Report and recommendation on the opioid crisis in Canada. House of Commons. 2016. Available from: https:\/\/www.ourcommons.ca\/documentviewer\/en\/42-1\/HESA\/report-6\/page-5."},{"key":"22777_CR27","doi-asserted-by":"publisher","unstructured":"Krassowski M. Complex. 2022. Upset. https:\/\/doi.org\/10.5281\/zenodo.3700590.","DOI":"10.5281\/zenodo.3700590"},{"issue":"12","key":"22777_CR28","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","volume":"20","author":"A Lex","year":"2014","unstructured":"Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: Visualization of Intersecting Sets. IEEE Trans Visual Comput Graphics. 2014;20(12):1983\u201392. https:\/\/doi.org\/10.1109\/TVCG.2014.2346248.","journal-title":"IEEE Trans Visual Comput Graphics"},{"key":"22777_CR29","unstructured":"Guide to drug combinations. Drug combinations - TripSit wiki. Version 4. 2019. Available from: https:\/\/combo.tripsit.me\/."},{"key":"22777_CR30","unstructured":"Government of Canada. Health Canada Drug Analysis Service. At-a-glance: New psychoactive substances in Canada - 2022. Longueuil (QC), 2023. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/new-psychoactive-substances-canada-2022.html."},{"key":"22777_CR31","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario). Novel non-fentanyl synthetic opioids: risk assessment and implications for practice. Toronto, ON: Queen's Printer for Ontario; 2021."},{"key":"22777_CR32","unstructured":"Gomes T, et al. Patterns of medication and healthcare utilization among individuals who succumbed to opioid-related toxicity during the COVID-19 pandemic in Ontario. Vancouver, BC: Ontario Drug Policy Research Network; 2022."},{"key":"22777_CR33","unstructured":"Canadian Institute for Health Information. Version 2022 ICD-10-CA\/CCI classifications, Canadian Coding Standards and related products. 2022. Available from: https:\/\/www.cihi.ca\/en\/version-2022-icd-10-cacci-classifications-canadian-coding-standards-and-related-products#v2022. Accessed 20 Nov 2023."},{"key":"22777_CR34","first-page":"19","volume":"1","author":"B Fischer","year":"2023","unstructured":"Fischer B. The continuous opioid death crisis in Canada: changing characteristics and implications for path options forward. Lancet Regional Health-Americas. 2023;1:19.","journal-title":"Lancet Regional Health-Americas"},{"issue":"1","key":"22777_CR35","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1186\/s12889-022-12469-9","volume":"22","author":"H Palis","year":"2022","unstructured":"Palis H, Xavier C, Dobrer S, Desai R, Sedgemore KO, Scow M, Lock K, Gan W, Slaunwhite A. Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study. BMC Public Health. 2022;22(1):2084. https:\/\/doi.org\/10.1186\/s12889-022-12469-9.","journal-title":"BMC Public Health"},{"key":"22777_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.029.","journal-title":"Drug Alcohol Depend"},{"issue":"102","key":"22777_CR37","doi-asserted-by":"publisher","first-page":"103602","DOI":"10.1016\/j.drugpo.2022.103602","volume":"1","author":"CD Lukac","year":"2022","unstructured":"Lukac CD, Steinberg A, Papamihali K, Mehta A, Lock K, Buxton JA. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey. Int J Drug Policy. 2022;1(102):103602. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103602.","journal-title":"Int J Drug Policy"},{"key":"22777_CR38","doi-asserted-by":"publisher","unstructured":"Payer DE, Young MM, Maloney-Hall B, et al. Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures, drug checking and urine toxicology. Ottawa. Canadian Centre on Substance Use and Addiction. 2020. https:\/\/doi.org\/10.35994\/canadian-centre-on-substance-use-and-addiction.64962.","DOI":"10.35994\/canadian-centre-on-substance-use-and-addiction.64962"},{"key":"22777_CR39","unstructured":"Health Canada. Spotlight: The evolution of fentanyl in Canada over the past 11 years. 2023. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/publications\/healthy-living\/evolution-fentanyl-canada-11-years\/evolution-fentanyl-canada-11-years-en.pdf."},{"key":"22777_CR40","unstructured":"Health Canada. Drug Analysis Service Trends 2012\u20132018. 2019. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/drug-analysis-service\/2018-drug-analysis-service-trends.html."},{"issue":"190","key":"22777_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.026","volume":"1","author":"KW Tupper","year":"2018","unstructured":"Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;1(190):242\u20135. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.026.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"22777_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1213\/ANE.0000000000004532","volume":"130","author":"LK Dunn","year":"2020","unstructured":"Dunn LK, Sun EC. Mind over matter: reducing perioperative opioid use through patient education. Anesth Analg. 2020;130(3):556\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000004532.","journal-title":"Anesth Analg"},{"issue":"4","key":"22777_CR43","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.japh.2020.02.003","volume":"60","author":"NN Kadakia","year":"2020","unstructured":"Kadakia NN, Rogers RL, Reed JB, Dark ER, Plake KI. Patient education interventions for prescription opioids: a systematic review. J Am Pharm Assoc. 2020;60(4):e31-42. https:\/\/doi.org\/10.1016\/j.japh.2020.02.003.","journal-title":"J Am Pharm Assoc"},{"key":"22777_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/JPR.S45957","volume":"5","author":"LS Wallace","year":"2013","unstructured":"Wallace LS, Wexler RK, Miser WF, McDougle L, Haddox JD. Development and validation of the patient opioid education measure. J Pain Res. 2013;5:663\u201381. https:\/\/doi.org\/10.2147\/JPR.S45957.","journal-title":"J Pain Res"},{"issue":"4","key":"22777_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/PHH.0000000000000672","volume":"24","author":"AM Peckham","year":"2018","unstructured":"Peckham AM, Niculete ME, Steinberg H, Boggs DL. A survey of prescribers\u2019 attitudes, knowledge, comfort, and fear of consequences related to an opioid overdose education and naloxone distribution program. J Public Health Manag Pract. 2018;24(4):310\u20137. https:\/\/doi.org\/10.1097\/PHH.0000000000000672.","journal-title":"J Public Health Manag Pract"},{"issue":"4","key":"22777_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/AJP.0000000000000279","volume":"32","author":"CS Hwang","year":"2016","unstructured":"Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Primary care physicians\u2019 knowledge and attitudes regarding prescription opioid abuse and diversion. Clin J Pain. 2016;32(4):279\u201384. https:\/\/doi.org\/10.1097\/AJP.0000000000000279.","journal-title":"Clin J Pain"},{"issue":"5","key":"22777_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/pm\/pny146","volume":"20","author":"DP Alford","year":"2019","unstructured":"Alford DP, Lazure P, Murray S, Hardesty I, Krause JR, White JL. National trends in prescription opioid risk mitigation practices: Implications for prescriber education. Pain Med. 2019;20(5):907\u201315. https:\/\/doi.org\/10.1093\/pm\/pny146.","journal-title":"Pain Med"},{"key":"22777_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40122-019-0136-1","volume":"8","author":"JV Pergolizzi Jr","year":"2019","unstructured":"Pergolizzi JV Jr, Varrassi G, Paladini A, LeQuang J. Stopping or decreasing opioid therapy in patients on chronic opioid therapy. Pain Ther. 2019;8:163\u201376. https:\/\/doi.org\/10.1007\/s40122-019-0136-1.","journal-title":"Pain Ther"},{"key":"22777_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-018-0210-4","volume":"15","author":"P Voon","year":"2018","unstructured":"Voon P, Greer AM, Amlani A, Newman C, Burmeister C, Buxton JA. Pain as a risk factor for substance use: A qualitative study of people who use drugs in British Columbia. Canada Harm Reduct J. 2018;15:1\u20139. https:\/\/doi.org\/10.1186\/s12954-018-0210-4.","journal-title":"Canada Harm Reduct J"},{"key":"22777_CR50","doi-asserted-by":"publisher","unstructured":"St. Marie B. Health care experiences when pain and substance use disorder coexist: \u201cJust because I'm an addict doesn't mean I don't have pain\u201d. Pain Medicine. 2014;15(12):2075\u201386. https:\/\/doi.org\/10.1111\/pme.12530.","DOI":"10.1111\/pme.12530"},{"issue":"200","key":"22777_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.03.026","volume":"1","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;1(200):95\u2013114. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.03.026.","journal-title":"Drug Alcohol Depend"},{"key":"22777_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/bmj.j760","volume":"14","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis. BMJ. 2017;14:356. https:\/\/doi.org\/10.1136\/bmj.j760.","journal-title":"BMJ"},{"key":"22777_CR53","unstructured":"Government of Canada. Benzodiazepines. 2021. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/controlled-illegal-drugs\/benzodiazepines.html."},{"key":"22777_CR54","doi-asserted-by":"crossref","unstructured":"Nielsen S, Van Hout MC. Over-the-counter codeine from therapeutic use to dependence, and the grey areas in between. Non-medical and Illicit Use of Psychoactive Drugs. 2017:59\u201375.","DOI":"10.1007\/7854_2015_422"},{"issue":"1","key":"22777_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1874402800902010016","volume":"2","author":"MF Andreasen","year":"2009","unstructured":"Andreasen MF, Lindholst C, Kaa E. Adulterants and diluents in heroin, amphetamine, and cocaine found on the illicit drug market in Aarhus. Denmark Open Foren Sci J. 2009;2(1):16\u201320.","journal-title":"Denmark Open Foren Sci J"},{"issue":"12","key":"22777_CR56","first-page":"38","volume":"41","author":"M Saljoughian","year":"2016","unstructured":"Saljoughian M. Acetaminophen intoxication: a critical-care emergency. US Pharm. 2016;41(12):38\u201341.","journal-title":"US Pharm"},{"issue":"2","key":"22777_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3109\/14659890009053078","volume":"5","author":"G Akram","year":"2000","unstructured":"Akram G. Over-the-counter medication: an emerging and neglected drug abuse? J Subst Use. 2000;5(2):136\u201342. https:\/\/doi.org\/10.3109\/14659890009053078.","journal-title":"J Subst Use"},{"issue":"185","key":"22777_CR58","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.drugalcdep.2017.11.029","volume":"1","author":"N Baldwin","year":"2018","unstructured":"Baldwin N, Gray R, Goel A, Wood E, Buxton JA, Rieb LM. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. Drug Alcohol Depend. 2018;1(185):322\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.11.029.","journal-title":"Drug Alcohol Depend"},{"key":"22777_CR59","unstructured":"Thomson E, Lampkin H, Maynard R, Karamouzian M, Jozaghi E. The lessons learned from the fentanyl overdose crises in British Columbia, Canada."},{"issue":"49","key":"22777_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drugpo.2017.08.015","volume":"1","author":"L Wang","year":"2017","unstructured":"Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;1(49):32\u201340. https:\/\/doi.org\/10.1016\/j.drugpo.2017.08.015.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"22777_CR61","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/jcpt.13464","volume":"46","author":"JV Pergolizzi Jr","year":"2021","unstructured":"Pergolizzi JV Jr, Dahan A, LeQuang JA, Raffa RB. The conundrum of polysubstance overdose. J Clin Pharm Ther. 2021;46(5):1189\u201393. https:\/\/doi.org\/10.1111\/jcpt.13464.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"22777_CR62","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4236\/jss.2021.97041","volume":"9","author":"JV Pergolizzi Jr","year":"2021","unstructured":"Pergolizzi JV Jr, Varrassi G, LeQuang JA, Raffa RB. The challenge of polysubstance use overdose. Open J Soc Sci. 2021;9(7):529\u201342. https:\/\/doi.org\/10.4236\/jss.2021.97041.","journal-title":"Open J Soc Sci"},{"key":"22777_CR63","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bmj.k4893","volume":"11","author":"A Slaunwhite","year":"2024","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B, Crabtree A, Bach P, Krebs E, Dale L, Meilleur L. Effect of Risk Mitigation Guidance for opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024;11:384. https:\/\/doi.org\/10.1136\/bmj.k4893.","journal-title":"BMJ"},{"issue":"5","key":"22777_CR64","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11524-022-00607-1","volume":"99","author":"A Lvsins","year":"2022","unstructured":"Lvsins A, MacKinnon L, Bowles JM, Slaunwhite A, Bardwell G. Overdose prevention and housing: A qualitative study examining drug use, overdose risk, and access to safer supply in permanent supportive housing in Vancouver. Canada J Urban Health. 2022;99(5):855\u201364. https:\/\/doi.org\/10.1007\/s11524-022-00607-1.","journal-title":"Canada J Urban Health"},{"issue":"5","key":"22777_CR65","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/add.14567","volume":"114","author":"SG Mars","year":"2019","unstructured":"Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2019;114(5):774\u201380. https:\/\/doi.org\/10.1111\/add.14567.","journal-title":"Addiction"},{"issue":"1","key":"22777_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-015-0088-4","volume":"12","author":"A Amlani","year":"2015","unstructured":"Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia. Canada Harm Reduct J. 2015;12(1):1\u20137. https:\/\/doi.org\/10.1186\/s12954-015-0088-4.","journal-title":"Canada Harm Reduct J"},{"issue":"3","key":"22777_CR67","doi-asserted-by":"publisher","first-page":"E231","DOI":"10.1503\/cmaj.151346","volume":"288","author":"D Kelsall","year":"2016","unstructured":"Kelsall D, Bowes MJ. No standards: medicolegal investigation of deaths. Can Med Assoc J. 2016;288(3):E231\u20134. https:\/\/doi.org\/10.1503\/cmaj.151346.","journal-title":"Can Med Assoc J"},{"issue":"15","key":"22777_CR68","doi-asserted-by":"publisher","first-page":"E527","DOI":"10.1503\/cmaj.231386","volume":"196","author":"M Bowes","year":"2024","unstructured":"Bowes M, Strang R, Huyer D. Use of data from death investigation systems to support community health and prevent premature deaths in Canada. CMAJ. 2024;196(15):E527-9.","journal-title":"CMAJ"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22777-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-22777-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22777-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:45:10Z","timestamp":1767789910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-22777-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["22777"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-22777-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4631651\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Public Health Agency of Canada Research Ethics Board (REB 2018-027P), the University of Manitoba Health Research Ethics Board (HS22710), and the Newfoundland and Labrador Health Research Ethics Board (20200153). The data used in this study was de-identified. Upon reviewing our privacy protocol, all three Research Ethics Boards approved the study without requiring consent from the individuals to whom the information relates based on Article 5.5A of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}